Biophan Announces Peer M. Portner, PhD, Appointed to MYOTECH Board of Directors.

Internationally Recognized Pioneer of First Permanently Implanted Mechanical Cardiac Assist System Joins Board

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, announces the appointment of Peer M. Portner, PhD, FACC, FAHA, developer of the first permanently implanted mechanical cardiac assist system, to the MYOTECH, LLC Board of Directors. Biophan and MYOTECH are co-developing MYOTECH's unique cardiac support system designed to treat many types of acute heart failure.

Dr. Portner has enjoyed a rare blend of leadership in biomedical industry and academia. An internationally respected authority on mechanically assisted circulation and one of the pioneers in artificial organs, Dr. Portner led the development, clinical application, and commercialization of the Novacor Heart Assist System, designed for long-term circulatory support in patients with terminal heart failure. Clinical evaluation was initiated at Stanford University Medical Center in 1984 with the world's first successful bridge to transplant. Utilization subsequently expanded globally to more than a hundred leading medical centers in over twenty countries. Dr. Portner has published extensively, lectured widely, and has been awarded sixteen patents. He has served as President of the American Society for Artificial Internal Organs and of the American Institute for Medical and Biological Engineering, on many committees of other professional organizations, and is currently a Trustee of the International Federation for Artificial Organs.

Dr. Portner commented, "I am pleased to be a part of the development and commercialization of MYOTECH's cardiac support system. Its unique characteristics offer significant advantages over other currently available circulatory support systems. Its potential for cost effectiveness, combining the lack of blood contact and rapid insertion without the need for specialized surgical facilities, will help to create a very large market for the treatment of many types of acute heart failure."

Jeffrey L. Helfer, President of Biophan's Cardiovascular Division and CEO and President of MYOTECH, said, "Dr. Portner is a scientist and entrepreneur of the highest caliber and we are honored to have him on our team. Dr. Portner's three decades of experience in the development and commercialization of cardiac support systems is a tremendous asset to MYOTECH and Biophan as we move MYOTECH's cardiac support system through clinical evaluation, regulatory approval, and to market."

Dr. Portner has been Consulting Professor of Cardiothoracic Surgery at the Stanford University School of Medicine since 1989 (previously Consulting Associate Professor of Cardiovascular Surgery since 1977). Dr. Portner was President, CEO, and founder of Novacor Medical Corporation in Oakland, California. Following its acquisition in 1988 by Baxter Healthcare Corporation, he was President, then Chairman, and until mid-2000 Chairman Emeritus of the Novacor Division of Baxter.

Dr. Portner received his undergraduate and graduate education at McGill University in Montreal, Canada, where he was a University Scholar and was subsequently a National Research Council Fellow at Oxford University.

About MYOTECH, LLC

MYOTECH, LLC, is a privately-held medical technology development company, formed in 2003 to commercialize a family of medical products based upon Direct Mechanical Ventricular Actuation ("DMVA") cardiac support technology. This technology has permitted the development of minimally invasive heart support devices that promise to be more broadly available and to provide safer, more effective, and less expensive treatment for patients with many types of heart failure. MYOTECH has relationships with leading physicians and medical institutions that are assisting MYOTECH in the commercialization of its technology. MYOTECH has several pending patents pertaining to the DMVA technology.

About Biophan

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company's technologies that improve the MRI safety and image compatibility of medical devices are licensed to leading device manufacturers. In addition, the Company is helping to commercialize MYOTECH's new MRI-compatible cardiac recovery system which has significant potential to improve the treatment of many forms of heart disease. Biophan Technologies, Inc. holds a 42% interest in MYOTECH with rights to acquire a majority position, and is leading MYOTECH's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.